China CDE Approves Global Phase III Study of Olverembatinib for SDH-Deficient GIST
SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 — Ascentage Pharma (6855.HK), a global biopharmaceutical…
SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 — Ascentage Pharma (6855.HK), a global biopharmaceutical…